Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

2307194-35-8Abiraterone-beta-D-Glucuronide

● Under Development

Katalog-Nr.::	VL830048
CAS-Nr.::	2307194-35-8
Summenformel::	C30H39NO7
Molare Masse::	525.65 g/mol

Wie können wir helfen?

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 2307194-35-8

Parent drug

Abiraterone

IUPAC-Name

(2S, 4R, 5R, 6R)-6-(((3S, 8R, 9S, 10R, 13S, 14S)-10, 13-dimethyl-17-(pyridin-3-yl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3, 4, 5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid

Pharmakopöe-Synonyme

N/A

Other Synonyms

(3Î²)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Î²-D-Glucuronide

SMILES

O=C([C@@H]1C(O)[C@@H](O)[C@@H](O)[C@H](O[C@H]2CC[C@]3(C)[C@@]4([H])CC[C@]5(C)C(C6=CC=CN=C6)=CC[C@@]5([H])[C@]4([H])CC=C3C2)O1)O

InChI

InChI=1S/C30H39NO7/c1-29-11-9-18(37-28-25(34)23(32)24(33)26(38-28)27(35)36)14-17(29)5-6-19-21-8-7-20(16-4-3-13-31-15-16)30(21,2)12-10-22(19)29/h3-5,7,13,15,18-19,21-26,28,32-34H,6,8-12,14H2,1-2H3,(H,35,36)/t18-,19-,21-,22-,23+,24?,25+,26-,28+,29-,30+/m0/s1

Beschreibung

Abiraterone-beta-D-Glucuronide or (2S,4R,5R,6R)-6-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid, it is inhibits CYP17A1 in a selective and irreversible manner and is used in the treatment of prostate cancer.

References

Thakur, Abhimanyu, et al. â€œAbiraterone Acetate in the Treatment of Prostate Cancer.â€ Biomedicine & Pharmacotherapy, vol. 101, May 2018, pp. 211â€“218, 10.1016/j.biopha.2018.02.067.